Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael A Papagikos

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Oncology (Williston Park, N.Y.)|May 17, 2015
Commentary (Papagikos/Lee): Permanent Prostate BrachytherapyMichael A Papagikos, W Robert Lee
Journal of the American College of Radiology : JACR|April 7, 2007
Publication rate of abstracts from the annual ASTRO meeting: comparison with other organizationsMichael A Papagikos, Peter J Rossi, W Robert Lee
The Lancet. Oncology|April 7, 2005
Lessons learned from randomised clinical trials in adult low grade gliomaMichael A Papagikos, Edward G Shaw, Volker W Stieber
International Journal of Radiation Oncology, Biology, Physics|February 7, 2019
Carolina HurricanesTrevor J Royce, Michael A Papagikos, Patrick D Maguire, et al.
Radiation Oncology (London, England)|January 15, 2017
Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancerMatthew J Boyer, Michael A Papagikos, Rex Kiteley, et al.
Urology|February 8, 2006
Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancerPeter J Rossi, Peter E Clark, Michael A Papagikos, et al.
Brachytherapy|December 14, 2005
Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?Michael A Papagikos, Allan F Deguzman, Peter J Rossi, et al.
American Journal of Clinical Oncology|April 7, 2007
A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy aloneMichael A Papagikos, Peter J Rossi, James J Urbanic, et al.
International Journal of Radiation Oncology, Biology, Physics|August 13, 2018
Cardiovascular Preventive Care and Coordination of Care in Prostate Cancer Survivors: A Multi-Institutional Prospective StudyJordan A Holmes, Roger F Anderson, Leroy G Hoffman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2013
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trialRenato G Martins, Upendra Parvathaneni, Julie E Bauman, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Oncology (Williston Park, N.Y.)|May 17, 2015
Commentary (Papagikos/Lee): Permanent Prostate BrachytherapyMichael A Papagikos, W Robert Lee
Journal of the American College of Radiology : JACR|April 7, 2007
Publication rate of abstracts from the annual ASTRO meeting: comparison with other organizationsMichael A Papagikos, Peter J Rossi, W Robert Lee
The Lancet. Oncology|April 7, 2005
Lessons learned from randomised clinical trials in adult low grade gliomaMichael A Papagikos, Edward G Shaw, Volker W Stieber
International Journal of Radiation Oncology, Biology, Physics|February 7, 2019
Carolina HurricanesTrevor J Royce, Michael A Papagikos, Patrick D Maguire, et al.
Radiation Oncology (London, England)|January 15, 2017
Toxicity and quality of life report of a phase II study of stereotactic body radiotherapy (SBRT) for low and intermediate risk prostate cancerMatthew J Boyer, Michael A Papagikos, Rex Kiteley, et al.
Urology|February 8, 2006
Percentage of positive biopsies associated with freedom from biochemical recurrence after low-dose-rate prostate brachytherapy alone for clinically localized prostate cancerPeter J Rossi, Peter E Clark, Michael A Papagikos, et al.
Brachytherapy|December 14, 2005
Dosimetric quantifiers for low-dose-rate prostate brachytherapy: is V(100) superior to D(90)?Michael A Papagikos, Allan F Deguzman, Peter J Rossi, et al.
American Journal of Clinical Oncology|April 7, 2007
A simple model predicts freedom from biochemical recurrence after low-dose rate prostate brachytherapy aloneMichael A Papagikos, Peter J Rossi, James J Urbanic, et al.
International Journal of Radiation Oncology, Biology, Physics|August 13, 2018
Cardiovascular Preventive Care and Coordination of Care in Prostate Cancer Survivors: A Multi-Institutional Prospective StudyJordan A Holmes, Roger F Anderson, Leroy G Hoffman, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 6, 2013
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trialRenato G Martins, Upendra Parvathaneni, Julie E Bauman, et al.
Pageof 2